Seeking Alpha

Seeking Alpha Portfolio App for iPad

John Eastman

John Eastman picture

Profile

Send Message

View as an RSS Feed

View John Eastman's Articles BY TICKER:

Trius Therapeutics Is A Strong Investment Short And Long Term
on Thu, Mar 21 • CBST, TSRX • 16 Comments
The Validity And Risk Of Keryx Biopharmaceuticals
on Wed, Mar 20 • KERX • 9 Comments
Now Is The Time To Pay Attention To InVivo
on Fri, Mar 1 • NVIV.OB • 14 Comments
Is Now The Time To Jump Into Halozyme?
on Wed, Feb 13 • HALO • 3 Comments
Google, Microsoft, And Apple Are Likely Using Technology Held By Mobivity Holdings
on Fri, Feb 8 • MFON.OB • 1 Comment
Why The Trius Offering Is A Positive Move
on Wed, Jan 23 • TSRX • 4 Comments
The Upward Climb Of Halozyme Therapeutics
on Mon, Jan 14 • BAX, PFE, VPHM • Comment!
Looking At Dendreon Again
on Fri, Jan 11 • DNDN • 4 Comments
What Is Keryx Biopharmaceuticals And Why Does It Matter?
on Tue, Jan 8 • KERX • 9 Comments
Trius Quickens Pace Towards Commercialization With FDA Designation For Tedizolid Phosphate
on Mon, Jan 7 • TSRX • Comment!
Halozyme Therapeutics's Key Deal With Pfizer Is Significant
on Thu, Jan 3 • PFE, HALO • 1 Comment
Trius Therapeutics: A Long, Stable, And Steady Play
on Thu, Dec 6, 2012 • TSRX • 5 Comments
The Company You Keep Speaks Volumes: Novabay And Trius
on Tue, Oct 9, 2012 • NBY, TSRX • 2 Comments
Trius Therapeutics: Slow, Steady And Cerebral
on Tue, Sep 4, 2012 • TSRX • Comment!
Fall Catalysts To Watch
on Fri, Aug 31, 2012 • DIA, SPY • 10 Comments
A 1-Day Snapshot Of Firms Related To The Apple-Samsung Electronics Case
on Wed, Aug 29, 2012 • GOOG, MSFT, NOK • 3 Comments
What Is Nuance Communications, And Why Does It Matter?
on Tue, Aug 21, 2012 • AUTH, NUAN • 4 Comments
Novabay Pharmaceuticals, Inc, An Opportunity In Progress
on Fri, Aug 10, 2012 • NBY • 1 Comment
On The Heels Of Chemo-Approved Cancer Drugs
on Mon, Apr 30, 2012 • LLY, MRK, NWBO • 3 Comments
For All Practical Purposes Synergy Pharmaceuticals Makes Sense
on Tue, Apr 17, 2012 • IRWD, SGYP • Comment!
Why Trius Therapeutics Is A Gem In The Innovative Antibiotics Market
on Fri, Apr 13, 2012 • BAYZF.PK, TSRX • 1 Comment
Inside Opko Health
on Mon, Mar 26, 2012 • TEVA, OPK • 2 Comments
Why Some Trends Matter, Even When There Is A Hiccup
on Fri, Mar 2, 2012 • PFE, GSK, MRK • 1 Comment
How A Scientific Partnership Is Moving Forward With Invivo And The Miami Project
on Wed, Feb 29, 2012 • NVIV.OB • 6 Comments
A Different Face For Facebook
on Mon, Feb 27, 2012 • GOOG, MSFT, FB • Comment!
Prolor And Other Israel-Based Medical Developments Figure Prominently On World Scene
on Mon, Feb 27, 2012 • PBTH • 1 Comment
Sifting Through Ampio Pharmaceuticals' Pipeline
on Wed, Feb 22, 2012 • AMPE • 1 Comment
The InVivo Effect
on Tue, Feb 14, 2012 • GERN, NVIV.OB • 3 Comments
ImmunoCellular: The Potential For A Cancer Vaccine
on Tue, Nov 22, 2011 • DNDN, IMUC • 2 Comments
Neostem May Have The Right Mix Of Assets To Excel In Cell Therapies
on Tue, Oct 4, 2011 • NBS • 1 Comment
Whether There Is Value To Be Had In 'Rudderless' Yahoo
on Thu, Sep 22, 2011 • GOOG, GRPN, YHOO • Comment!
Why IBM Still Matters
on Sat, Sep 17, 2011 • IBM, WLP • 5 Comments